TAEKDA, Vortioxetine filed in USA – A Me-Too SSRI in Highly Genericized Market Will Still be Able to Generate ~$2b

Date: 2015-07

Takeda announced today NDA submission of vortioxetine (Lu AA21004, 5HT uptake inhibitor, partnered with Lundbeck) for major depressive disorder (MDD) in adult patients. Despite the fact that antidepressant market will be fully genericized by 2013 when Cymbalta (Lilly, WW peak sales pot ~$7b from all indications) will go off patent and most of these generics will belong to SNRI class – high unmet need (poor tolerability, moderate efficacy, and thus switching as an unavoidable phenomenon among existing options), and certain advantages with vortioxetine will still allow it to capture ~5-7% of market share – this translates into ~$2b opportunity

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample